Volitionrx Ltd (VNRX)

$0.19 -0.01 (-2.91%)
Market Cap 25.81M
Revenue (ttm) 1.23M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,192.68%
Debt to Equity Ratio -0.22
Volume 1,423,700
Avg Vol 2,103,612
Day's Range N/A - N/A
Shares Out 135.57M
Stochastic %K 26%
Beta 1.33
Analysts Strong Sell
Price Target $2.06

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices
Sector: Healthcare
Phone: 646 650 1351
Address:
1489 West Warm Springs Road, Suite 110, Henderson, United States
2021er
2021er Mar. 15 at 12:05 PM
$VNRX Cats May Hold the Key to Treating Human Cancer https://share.google/MRwljrGMuk7aN7R8Q
0 · Reply
Daf88
Daf88 Mar. 13 at 5:32 PM
$VNRX the manipulation in this stock is unbearable. Permission from board for this to occur should be investigated.
0 · Reply
moemog
moemog Mar. 10 at 3:40 PM
$VNRX 🚀⏰ :))))))))))))))
0 · Reply
ZacksSCR
ZacksSCR Mar. 9 at 2:37 PM
$VNRX: Review of Recent Events by Pillar; 4Q & Year End 2025 Results Expected in late March https://buff.ly/YlPIYlh
0 · Reply
BioTuesdays
BioTuesdays Mar. 6 at 7:24 PM
$VNRX has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. https://biotuesdays.com/2026/03/06/volition-announces-first-ever-automated-nu-q-vet-cancer-test/
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 6 at 7:22 PM
InvestorNewsBreaks – $VNRX Completes Automation Validation for Nu.Q Vet Cancer Test in Japan https://ibn.fm/Oa9w8
0 · Reply
Charleseatworld
Charleseatworld Mar. 6 at 1:22 PM
$VNRX loading up here
2 · Reply
TheTradeXchange
TheTradeXchange Mar. 6 at 1:10 PM
$VNRX VNRX VNRX VNRX - Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
0 · Reply
StockNews_Live
StockNews_Live Mar. 6 at 1:10 PM
$VNRX VolitionRx Limited announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japa…
0 · Reply
moemog
moemog Mar. 5 at 1:48 PM
$VNRX 🚀 ⏰
0 · Reply
Latest News on VNRX
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Mar 6, 2026, 8:10 AM EST - 9 days ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 25, 2026, 8:10 AM EST - 18 days ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Feb 10, 2026, 8:07 AM EST - 4 weeks ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 9, 2026, 5:20 PM EST - 4 weeks ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

Feb 4, 2026, 8:45 AM EST - 5 weeks ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 30, 2026, 8:50 AM EST - 6 weeks ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Jan 27, 2026, 8:00 AM EST - 6 weeks ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 20, 2026, 8:25 AM EST - 7 weeks ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 16, 2026, 8:45 AM EST - 2 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 9:15 AM EST - 2 months ago

VolitionRx Secures $2.0 Million in Funding

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Jan 8, 2026, 8:45 AM EST - 2 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Volition Issues Business Review 2025

Dec 17, 2025, 8:45 AM EST - 3 months ago

Volition Issues Business Review 2025

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 11, 2025, 9:00 AM EST - 3 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 8, 2025, 9:00 AM EST - 3 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

Dec 4, 2025, 9:00 AM EST - 3 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Nov 25, 2025, 8:45 AM EST - 3 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 12:51 PM EST - 4 months ago

VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 13, 2025, 4:10 PM EST - 4 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Nov 10, 2025, 8:45 AM EST - 4 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 17, 2025, 8:00 AM EDT - 5 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 10, 2025, 8:30 AM EDT - 5 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 5 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

VolitionRx Limited - Special Call

Oct 8, 2025, 4:56 PM EDT - 5 months ago

VolitionRx Limited - Special Call

Volition Sponsors Upcoming GenomeWeb Webinar

Oct 2, 2025, 8:45 AM EDT - 5 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Volition Signs Co-Marketing and Services Agreement with Hologic

Sep 29, 2025, 9:30 AM EDT - 5 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Volition Signs First Human Out Licensing Deal

Sep 9, 2025, 8:45 AM EDT - 6 months ago

Volition Signs First Human Out Licensing Deal

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

Aug 15, 2025, 2:24 PM EDT - 7 months ago

VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 14, 2025, 4:10 PM EDT - 7 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 8, 2025, 8:30 AM EDT - 7 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Aug 4, 2025, 4:01 PM EDT - 7 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 16, 2025, 8:00 AM EDT - 8 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jul 8, 2025, 8:00 AM EDT - 8 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 12, 2025, 8:30 AM EDT - 9 months ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

Jun 4, 2025, 9:00 PM EDT - 10 months ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025, 8:30 AM EDT - 10 months ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025, 7:19 PM EDT - 10 months ago

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025, 5:37 PM EDT - 10 months ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025, 8:30 AM EDT - 10 months ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025, 8:30 AM EDT - 11 months ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Apr 29, 2025, 8:30 AM EDT - 11 months ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 12:31 AM EDT - 1 year ago

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 26, 2025, 8:00 AM EDT - 1 year ago

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 25, 2025, 9:30 AM EDT - 1 year ago

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Volition Proudly Sponsors the 44th ISICEM Congress

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Volition Proudly Sponsors the 44th ISICEM Congress

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

2021er
2021er Mar. 15 at 12:05 PM
$VNRX Cats May Hold the Key to Treating Human Cancer https://share.google/MRwljrGMuk7aN7R8Q
0 · Reply
Daf88
Daf88 Mar. 13 at 5:32 PM
$VNRX the manipulation in this stock is unbearable. Permission from board for this to occur should be investigated.
0 · Reply
moemog
moemog Mar. 10 at 3:40 PM
$VNRX 🚀⏰ :))))))))))))))
0 · Reply
ZacksSCR
ZacksSCR Mar. 9 at 2:37 PM
$VNRX: Review of Recent Events by Pillar; 4Q & Year End 2025 Results Expected in late March https://buff.ly/YlPIYlh
0 · Reply
BioTuesdays
BioTuesdays Mar. 6 at 7:24 PM
$VNRX has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. https://biotuesdays.com/2026/03/06/volition-announces-first-ever-automated-nu-q-vet-cancer-test/
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 6 at 7:22 PM
InvestorNewsBreaks – $VNRX Completes Automation Validation for Nu.Q Vet Cancer Test in Japan https://ibn.fm/Oa9w8
0 · Reply
Charleseatworld
Charleseatworld Mar. 6 at 1:22 PM
$VNRX loading up here
2 · Reply
TheTradeXchange
TheTradeXchange Mar. 6 at 1:10 PM
$VNRX VNRX VNRX VNRX - Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
0 · Reply
StockNews_Live
StockNews_Live Mar. 6 at 1:10 PM
$VNRX VolitionRx Limited announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japa…
0 · Reply
moemog
moemog Mar. 5 at 1:48 PM
$VNRX 🚀 ⏰
0 · Reply
Daf88
Daf88 Mar. 4 at 5:44 PM
$HUMA finally this is looking nice! check as well $VNRX ABOUT TO TAKE OFF historically low market cap
0 · Reply
Daf88
Daf88 Mar. 4 at 5:44 PM
$CLNN this is looking nice! check as well $VNRX ABOUT TO TAKE OFF historically low market cap
0 · Reply
Daf88
Daf88 Mar. 4 at 3:37 PM
$RXRX this is moving up! Do not lose $VNRX it will as well take off from historical low market cap
0 · Reply
Daf88
Daf88 Mar. 4 at 3:36 PM
$CTXR finally! Lymphir sales moving this up. do not lose $VNRX they are pushing it down but soon it will break out due to potential
0 · Reply
Daf88
Daf88 Mar. 2 at 6:19 PM
$VNRX who the hell is pushing down each good news for this company? What is this lack of transparency and pure market manipulation?
2 · Reply
FyCkD_FuNnY
FyCkD_FuNnY Feb. 27 at 6:51 PM
$VNRX SP sucks, but I still believe in what they do... Colorectal/Lung/Ovarian cancer detection via Nu.Q Canine/ Feline cancer diagnosis via Nu.Q Vet Sepsis detection via Nu.Q NETs H3.1 Low on Cash $6.1 from market offering will cover Q4 SGA costs (Oct'25) $2.0m funding will help cover Q1 SGA costs (Jan'26) Will receive a $5M milestone payment (Q2'26 possibly later) $7.3m DETECSEPS program in France (Q4'26 - Q1'27) Start of '27 should see the start to Profitability 137m +/- OS Lagoda Management 11.4m (Sold 1m+) 2-17-26 Vanguard Group 1.5m 1-29-26 Geode Cap 963k (Add 85k) 2-09-26 Blackrock 445k 2-12-26 State Street 311k (Add 43k) 2-13-26 CEO 3.5m 11-17-25 Director Innes 3.4m 1-22-26 Director Still 1.6m 1-22-26 Officer Rootsaert 1.1m 1-22-26
0 · Reply
Daf88
Daf88 Feb. 26 at 7:57 PM
$ALT check $VNRX amazing commercial execution with billionare addressable market ahead
1 · Reply
Daf88
Daf88 Feb. 26 at 7:56 PM
$NVDA while IA is doubtful about future, check $VNRX amazing commercial execution
0 · Reply
Daf88
Daf88 Feb. 26 at 7:56 PM
$PYPL in the meantime, check $VNRX amazing commercial execution for billionaire addressable market
0 · Reply
Daf88
Daf88 Feb. 26 at 7:55 PM
$DARE let’s push biotech, amazing opportunity for $VNRX Time for Dare will arrive soon but check news from Volition Rx it will soon take off do not lose the chance
0 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 26 at 12:40 PM
$VNRX
0 · Reply
TheRealStockRocket
TheRealStockRocket Feb. 26 at 12:10 PM
$VNRX to below...cause they had debt to pay off to gain all the clinical data research needed....Its just about go time...the note that drove it down from several dollars to these ridiculous prices is now extinguished. This is a bonaide squeezer in volume with all the ingredients. It can make and $IBRX type move.
0 · Reply